IHAM
TRIL

Integral Health Asset Management’s Trillium Therapeutics Inc. TRIL Stock Holding History

Integral Health Asset Management’s Portfolio TRIL Stock Details TRIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-150,000
Closed -$1.46M – 93
2021
Q2 		$1.46M Buy
+150,000
New +$1.41M 0.4% 63

Other funds holding TRIL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
OPU
Omni Partners US Irvine, California $1.95B AUM
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return

Integral Health Asset Management's TRIL Position: Q3 2021 in Review

Integral Health Asset Management sold out of Trillium Therapeutics Inc. (TRIL) in Q3 2021, closing a stake of 150,000 shares — an estimated $1.46M sold.

Integral Health Asset Management first reported a position in TRIL in Q2 2021 and held it in 1 quarter. The position peaked at $1.46M in Q2 2021. 182 funds tracked by Wall St. Rank hold TRIL as of Q3 2021.

  • Integral Health Asset Management reported no remaining Trillium Therapeutics Inc. position as of Q3 2021 after selling out during the quarter.
  • Integral Health Asset Management sold 150,000 Trillium Therapeutics Inc. shares in Q3 2021, an estimated $1.46M.
  • Integral Health Asset Management first reported a position in Trillium Therapeutics Inc. in Q2 2021 and held it in 1 quarter.
  • Integral Health Asset Management's Trillium Therapeutics Inc. position peaked at $1.46M in Q2 2021.
  • 182 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q3 2021.

Based on Integral Health Asset Management's 13F filing for Q3 2021, filed 12 Nov 2021.